

Fast Facts

- Founded in 2009 by serial entrepreneur Robert Taub
- Headquartered in Belgium with subsidiaries in Israel, Australia and US
- Led by a strong and experienced Management Team
- > Raised €79M in equity to date
- Genio®, a user-centered, CE-mark validated bilateral neurostimulation therapy
- Expansive IP portfolio and knowhow

- Targeting existing, fast growing OSA market
- OSA prevalence worldwide 936 million patients
- 425 million moderate-to-severe OSA patients eligible for therapy¹
- Large Hypoglossal Nerve Stimulation
 Market currently underpenetrated
- Yearly eligible HGNS patients –
 US and Europe/ANZ combined:
 1.1 million new patients
- >>\$20 billion revenue opportunity in Europe/ANZ and US

Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, including Obstructive Sleep Apnea (OSA)

MedTech





- Leadless & battery-free neurostimulator
- Bilateral simulation, unique to Nyxoah





(yoah)

Patient owning the therapy

- Digital Care Management (DCM) platform integrating diagnostic tools
- Live therapy optimization: Detect/Analyze/Adjust
- Al through data collection





Razor and blades model

- System software upgrade
- Disposable Patch annuity

The Genio® system – A novel and disruptive solution

Minimally invasive procedure

Bilateral stimulation

User-centered

Implantable Stimulator

Activation Chip and Disposable Patch

Charging Unit

Addressing unmet needs for OSA patients who have failed conventional therapy, including Continuous Positive Airway Pressure ("CPAP")

Strong Clinical Execution

CE mark approval

- >> BLAST OSA 27 patients
 - 2 publications
 - CE mark approval in 2019

Expand Genio® therapeutic indications

- >> BETTER SLEEP 44 patients
 - 9 ANZ centers
 - CCC represents 25% OSA patients

Demonstrate long-term safety and efficacy

- >> EliSA 110 patients
 - 20 EU centers in 5 countries
 - 5-year follow-up

FDA approval

- >> DREAM 134 patients
 - FDA approved IDE pivotal study in June 2020
 - Up to 26 centers

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

 $^{\rm 1}$ Benjafield, Adam V et al. Lancet Respir Med 2019 Aug; 7(8): 687-698

Indication for Use: Genio® is intended to treat adult patients suffering from moderate to severe Obstructive Sleep Apnea (OSA) and who have either not tolerated, have failed or refused Positive Airway Pressure (PAP) therapy. All rights reserved © 2020 Nyxoah S.A. All content on this brochure, including the texts, trademarks, service marks, logos, illustrations, photos, graphics, design, etc., are the property of Nyxoah S.A. Nyxoah S.A. owns all rights with respect to any of their trademarks, service marks, logos, and copyrights appearing on this brochure. Patented and design protected technology.

CE marked since 2019.

Caution – Investigational device in the United States. Limited by United States federal law to investigational use.

Nyxoah S.A. Rue Edouard Belin 12 1435 Mont-Saint-Guibert Belgium info@nyxoah.com +32 10 22 23 55

